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This  paper  examines  interdependencies  between  ﬁrms’  activities  in the realms  of open  science  and
commercial  product  development.  We  present  a theoretical  framework  that  outlines  when  a  ﬁrm’s
involvement  in academic  communities  enhances  its innovative  performance  in terms  of new  products  in
development.  We  argue  that the  disclosure  of  more,  valuable  R&D  work  in quality  scholarly  publicationseywords:
iotechnology
cience–industry collaborations
nnovation management
and  collaborations  with  academic  partners  positively  affect  ﬁrm  innovation.  We  further  hypothesize  a
differential  effect  of  adopting  open  science  strategies  on the  innovation  type,  being  more  pronounced
for  radical  innovations  than  for incremental  innovations.  We  empirically  analyze  a  unique  panel dataset
containing  information  on  the product  innovation  performance  and  R&D  activities  of 160 UK  therapeutic
biotechnology  ﬁrms  over  the  period  1998-  2009.  Our  results  from  count  data  models  on the  number  of
mentpen science new  products  in  develop
. Introduction
A growing number of ﬁrms in knowledge-intensive sectors
articipate in open science, a system of cumulative knowledge
roduction that facilitates the disclosure of scientiﬁc discoveries
hrough publications in academic journals (Dasgupta and David,
994; Ding, 2011; Gittelman and Kogut, 2003; Mukherjee and
tern, 2009). In fact, prominent ﬁrms have developed into core
ubs for scientiﬁc knowledge exchange in several ﬁelds. Whereas
n 1975 none of the 25 most-cited articles in Science were (co-)
uthored by researchers afﬁliated with ﬁrms, in 2009 there were
.1 Comparative research on the extent to which products and pro-
esses build on academic science across different sectors highlights
hat this development has been particularly potent in the life sci-
nces sector (Mansﬁeld, 1995, 1998). A single biotechnology ﬁrm,
enentech published 5038 articles in scientiﬁc journals over the
eriod 1976–2008, of which 249 in Science or Nature.2Despite success stories of ﬁrms like Genentech, signiﬁcant
ariation remains in the extent to which individual ﬁrms embrace
pen science strategies, with some ﬁrms adopting more open R&D
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models and others opting to adhere to more traditional, closed R&D
models. Scholarship suggests that the imprint left by founders plays
an important role in shaping corporate R&D strategies in general
and ﬁrms’ willingness to adopt open science practices in particular
(Ding, 2011; Jong, 2006; Murray, 2004; Powell and Sandholtz,
2012). Although the importance of organizational imprinting for
ﬁrms’ varying strategies in interacting with academic communities
is well understood, the dynamics governing the interdependencies
between ﬁrms’ activities across the realms of open science and
commercial product development remain less clearly deﬁned.
Existing studies highlight a range of beneﬁts for ﬁrms that
participate in open science, including the opportunity to learn
from academic collaborators (Almeida et al., 2011; Cockburn and
Henderson, 1998; Liebeskind et al., 1996; Zucker et al., 2002), to
enhance ﬁrms’ absorptive capabilities (Cohen and Levinthal, 1990;
Fabrizio, 2009; Fleming and Sorenson, 2004), to attract and retain
high-quality scientists (Stern, 2004), and to signal the possession
of strong scientiﬁc competences to external parties (Luo et al.,
2009; Polidoro and Theeke, 2012). However, other studies high-
light potential drawbacks for ﬁrms’ involvement in open systems
of knowledge exchange because of the conﬂicts that exist between
the institutional logics governing the realms of science and tech-
nology. For example, Gittelman and Kogut (2003) point out that
the production of high-proﬁle scientiﬁc papers actually harms the
production of high-value patents.Our research aims to explore boundary conditions that gov-
ern the beneﬁts of ﬁrms’ involvement in academic communities.
Speciﬁcally, we examine the impact of publishing better schol-
arly research and collaborating with university scientists on ﬁrm
reserved.
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nnovative performance. Building on insights from the sociology
f organizations and knowledge literature we propose conditions
nder which the stratiﬁcation logics of science and technol-
gy are mutually reinforcing: We  argue that the academic value
f ﬁrms’ publishing activities and the ties ﬁrms develop with
cademic laboratories positively affect ﬁrms’ ability to leverage
esources embedded in external open scientiﬁc systems of knowl-
dge exchange in internal R&D programs. However, we contend
hat this positive effect varies with the type of innovation and is
ore pronounced for radical than for incremental innovations.
To test our hypotheses we create a panel dataset containing
etailed information on the publishing and R&D activities of 160
K therapeutic biotechnology ﬁrms over the period 1998–2009.
his dataset allows us to analyze how variations in ﬁrms’ inter-
ctions with academic communities have an impact on ﬁrm R&D
roductivity, after controlling for R&D input related variables. The
iotechnology sector has proven a fruitful context, in which to
xamine the effect of adopting open science strategies on ﬁrm
nnovation for several reasons. First, there is no sector, in which
ommercial and academic research networks are so closely inter-
wined as these are in biotechnology (Mansﬁeld, 1995, 1998).
econd, the commercialisation environment and appropriability
egime in biotechnology are among the most supportive to open
xchanges of ideas across organizational boundaries in general and
he science–industry boundary in particular (e.g. Gans and Stern,
003; Teece, 1986). Third, for the speciﬁc purposes of this study, the
hoice of the setting of therapeutic biotechnology enables a system-
tic classiﬁcation and operationalization of the degree of novelty of
roduct innovations.
Our results from estimating negative binomial models on the
umber of new therapeutic projects entering clinical trials provide
upport for our main hypotheses. Speciﬁcally, our ﬁndings reveal
hat ﬁrms that disclose more, valuable R&D work in quality schol-
rly publications exhibit higher levels of innovative output in
erms of the new therapeutic projects these ﬁrms move into the
evelopment pipeline. Adding to previous work on the value of con-
ectedness to university scientists, we ﬁnd that while controlling
or ﬁrms’ publishing activity, pursuing research collaborations with
cientists at academic institutions further enhances ﬁrms’ innova-
ive performance. In addition, we ﬁnd that the beneﬁcial effect of
aking more substantive contributions to open science is a limited
ffect; while increasing a ﬁrm’s propensity to develop radically
nnovative products, it does not increase a ﬁrm’s propensity to
evelop incrementally innovative products.
Our research advances the literature on ﬁrms’ interactions
ithin open systems of knowledge exchange in two principal ways.
irst, it contributes to on-going debates about the interrelation-
hips that govern ﬁrms’ activities across the spheres of science
nd technology. While some suggest that corporate science that
s more highly valued in academic circles is associated with supe-
ior innovative performance (e.g. Almeida et al., 2011; Zucker
t al., 2002), others argue that a stronger performance by a ﬁrm
n one sphere is associated with a weaker performance in the other
phere (Gittelman and Kogut, 2003). We  highlight that open sci-
nce strategies have an overall positive effect on new products in
evelopment. Notably, this effect holds if the academic esteem of
rms’ scholarly contributions is taken into account, which some
uggest to be a drag on the production of commercially valuable
nowledge (Gittelman and Kogut, 2003). Consequently, we  extend
revious studies on positive effects of publishing and collaborat-
ng with university scientists on the importance of ﬁrm patents
Cockburn and Henderson, 1998), the timing and importance of
rm inventions (Fabrizio, 2009), and the number of patent families
Almeida et al., 2011).
Second, our study makes a contribution by deﬁning bound-
ry conditions for the efﬁcacy of efforts to enhance innovativelicy 43 (2014) 645–654
performance through open science strategies and advances schol-
arship on the challenges ﬁrms face in capturing value in open
innovation networks. Prior work for example highlights how
ﬁrms face behavioral constraints in managing too many academic
collaborations (Lavie and Drori, 2012; McFadyen and Cannella,
2004). Our study illuminates the contingent value of open science
strategies for the type of innovation outcome (e.g. radical or incre-
mental innovations) that ﬁrms focus on in R&D. By considering
the type of innovation, this work extends past research on the link
between the importance of inventions and the usage of scientiﬁc
and distant knowledge (Fabrizio, 2009; Fleming and Sorenson,
2004; Rosenkopf and Nerkar, 2001).
The remainder of this paper is organized as follows. First, we
present the conceptual motivation behind the study. We  subse-
quently construct our theoretical framework and develop testable
hypotheses. Next, we  describe the study design and the data used
to perform the empirical analyses. We  subsequently present and
discuss the results of our analyses. Finally, building on a discussion
of the generalizability of our ﬁndings, we  outline future research
directions.
2. Theory and hypotheses
Creative processes underlying product innovation in many
industries increasingly extend beyond the commercial realm. The
central role academic communities now play in fuelling product
innovation in sectors such as the biotechnology, nanotechnology,
and clean technology sectors exempliﬁes this trend (Cockburn and
Henderson, 1998; Fleming and Sorenson, 2004; Laursen and Salter,
2004; Liebeskind et al., 1996). To tap into creative processes in sci-
entiﬁc communities ﬁrms rely on so-called absorptive capabilities
that allow ﬁrms to assimilate and exploit external knowledge. The
development of such capabilities is a principal rationale for invest-
ments in in-house R&D (Cohen and Levinthal, 1990; Fabrizio, 2009;
Rosenberg, 1990).
Managers face a number of trade-offs in the organization of
in-house R&D. The extent to which ﬁrms adopt organizational
models associated with open science, and disclose and share
R&D ﬁndings, is among the most important of these trade-offs.
There used to be clear differences between organizational models
governing academic and commercial research, in particular with
regards to the willingness of researchers to disclose and share
work in open forums such as scientiﬁc journals (e.g. Dasgupta
and David, 1994). High levels of secrecy used to be the norm for
corporate R&D organizations, which were seen as necessitated by
the for-proﬁt orientation of these organizations. However, asser-
tions underlying traditional, closed corporate R&D models have
become increasingly contested with the rise of successful new
ﬁrms adopting open science strategies over recent decades (Ding,
2011; Fabrizio, 2009; Powell and Sandholtz, 2012). Such strategies
entail the incorporation of academic practices in corporate R&D
such as encouraging priority-based publishing of research ﬁndings,
sharing of proprietary knowledge with community members, and
showing deference to academic status hierarchies (Dasgupta and
David, 1994; Gittelman and Kogut, 2003; Kaplan and Murray, 2010;
Merton, 1968; Stephan, 1996).
The extent to which ﬁrms incorporate more open approaches
in interactions with academic communities has been linked to the
organizational imprint founders left on the R&D organizations of
these ﬁrms. Firms with a higher level of involvement of senior aca-
demic scientists during the formative development phase generally
embrace more academic, open approaches in the organization of
R&D. Firms with a more corporate imprint, at which managers and
researchers with an industry background play a more dominant
role during the formative development phase tend to stick to more
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raditional, closed organizational practices in R&D (Ding, 2011;
owell and Sandholtz, 2012). Although existing studies explain
ow ﬁrms follow distinctive paths in terms of the adoption of differ-
nt R&D models, the interdependencies governing ﬁrms’ activities
cross the realms of science and technology and the mechanisms
hrough which these interdependencies affect ﬁrms’ comparative
dvantages remain less well understood. Given the durability of
arying approaches to the adoption of open science strategies
mong life sciences ﬁrms (Ding, 2011; Powell and Sandholtz, 2012),
ur primary interest is not in determining whether open or closed
&D models (or any particular mix  of the two models) represent an
rganizational archetype that leads to universally superior innova-
ion outcomes. Instead, we will seek to outline boundary conditions
ithin which open science strategies that involve the disclosure of
&D in scientiﬁc publications perform better and to identify con-
ingent factors that might tilt trade-offs ﬁrms face in organizing
nteractions with academic communities.
.1. Firms’ contributions to science and ﬁrm innovation
Publishing confers various beneﬁts on ﬁrms in innovation pro-
esses. Existing work highlights how the scientiﬁc proﬁciency of
orporate researchers who publish is key to the development
f a ﬁrm’s absorptive capabilities in science-intensive industries
Fabrizio, 2009; Cockburn and Henderson, 1998). For example,
esearch on the early development of the biotechnology industry
ighlights that pharmaceutical R&D laboratories that tied com-
ensation and promotion decisions to workers’ publications were
ore successful in adapting to the era of biotechnology (Cockburn
nd Henderson, 1998; Henderson and Cockburn, 1994; Henderson,
994). However, the boundary conditions under which improved
bsorptive capabilities are helpful in supporting product innova-
ion remain less well understood.
A particularly vexing, unresolved issue is whether ﬁrms that
scend in the scientiﬁc stratiﬁcation order by disclosing and shar-
ng better science through publications derive advantages from this
scend. Some argue that investing in advancing a ﬁrm’s academic
tanding may  be a distraction and is not conducive to improv-
ng R&D performance as conﬂicting stratiﬁcation logics across the
ealms of science and technology prevent ﬁrms to carry over and
njoy an advantage gained in one realm in another realm. High-
ighting difﬁculties ﬁrms face in producing both publications and
atents that are widely cited, Gittelman and Kogut (2003) for exam-
le argue that what determines a ﬁrm’s ability to enjoy enhanced
bsorptive capabilities in science-based R&D is the proﬁciency of
rm researchers in their scientiﬁc subjects, not the level of aca-
emic recognition these researchers receive for publications.
We posit that disseminating better research in scientiﬁc
ommunities constitutes a source of comparative advantage in
dvancing corporate R&D goals. Scientiﬁc knowhow of commercial
alue is often tacitly held by members of academic communities,
articularly those members who are higher up in the scientiﬁc
tratiﬁcation order. Therefore, so-called star scientists have played
 critical role in the development of the biotechnology industry
nd confer a comparative advantage on the ﬁrms they associate
hemselves with (Liebeskind et al., 1996; Zucker et al., 1998).
Sociologists of knowledge highlight that scarce resources in sci-
nce such as tacit knowhow held by star scientists and collaboration
pportunities with top laboratories ﬂow disproportionally to those
ho are already situated higher up in scientiﬁc stratiﬁcation orders
e.g. Crane, 1965; Merton, 1968). Indeed, gaining a good standing
n academic communities is often seen as critical to securing access
o upstream intellectual resources in science-based R&D. Gans and
tern (2003) for example argue that litigious behavior by Johnson
 Johnson during the 1980s undermined the company’s reputation
n academic circles and put it at a disadvantage in securing criticallicy 43 (2014) 645–654 647
upstream R&D partners. Moreover, highly regarded corporate sci-
entists are better positioned as boundary spanners to gain access to
and build on upstream scientiﬁc knowledge (Hess and Rothaermel,
2011), and to create collaboration opportunities with academic sci-
entists (Hicks, 1995; Wang and Shapira, 2012). An important means
to enhance a ﬁrm’s standing in academic communities is to publish
more and better articles. For example, Darby et al. (1999) ﬁnd that
publications by star scientists afﬁliated with a ﬁrm, increase the
ﬁnancial valuation of this ﬁrm and Stuart et al. (2007) show a simi-
lar effect for ﬁrms’ ability to secure upstream licensing agreements
with universities. Accordingly, we  expect that ﬁrms with open sci-
ence strategies that produce better science enjoy a comparative
advantage in using critical R&D resources in product development
and our ﬁrst hypothesis is the following:
Hypothesis 1. Publishing quality scholarly research has a positive
effect on ﬁrms’ product innovation performance.
2.2. Academic collaborations and innovative performance in
science-based R&D
The decision with whom to partner in the development of open
science strategies is an important one and the inclusion of aca-
demic partners in such strategies can be beneﬁcial for a number
of reasons. First, individuals are important conduits for knowl-
edge ﬂows across organizations in general (e.g. Almeida and Kogut,
1999; Casper, 2007; Saxenian, 1994; Sorenson et al., 2006), and
across the science–industry barrier in particular (e.g. Casper and
Murray, 2005; Liebeskind et al., 1996; Thursby and Thursby, 2000;
Zucker et al., 1998). Apart from providing conduits for these ﬂows,
personal interactions in university collaborations also enhance
trust and increase the willingness of academic partners to share
knowhow (Bouty, 2000; Haeussler, 2011; Hicks, 1995). As a result,
corporate researchers in university collaborations enjoy additional
learning opportunities (Liebeskind et al., 1996; Zucker et al., 2002),
and such collaborations provide ﬁrms an edge in securing access
to novel, emerging science for use in proprietary R&D (Stuart
et al., 2007). Accordingly, the setting of university collaborations
increases the creativity of corporate researchers (Lavie and Drori,
2012; McFadyen and Cannella, 2004), and the speed of invention
processes researchers are engaged in (Fabrizio, 2009). Moreover,
university collaborations have a positive effect on the number
and quality of ﬁrm patents (Almeida et al., 2011; Fabrizio, 2009;
Cockburn and Henderson, 1998).
Second, university collaborations offer economies of scope and
scale opportunities, allowing ﬁrms to make more efﬁcient use
of ﬁnancial resources (e.g. Katz and Martin, 1997). In fact, ﬁrms
with university linkages incur lower R&D expenses while achiev-
ing higher levels of innovative output (George et al., 2002). Finally,
ﬁrms are able to tap into and beneﬁt from the reputation and collab-
oration networks of university partners (Wang and Shapira, 2012).
Building on these insights, we  anticipate collaborations with uni-
versity scientists to provide ﬁrms with a source of comparative
advantage in product innovation that is different from the bene-
ﬁt associated with publishing quality research and we posit the
following hypothesis:
Hypothesis 2. Collaborating with university scientists on schol-
arly publications has a positive effect on ﬁrms’ product innovation
performance.
2.3. Publishing quality scholarly research and innovation typeWe argue that the impact of open science strategies is contin-
gent on the type of innovations ﬁrms pursue, speciﬁcally whether
the emphasis in a ﬁrm’s R&D is on the development of radical
or incremental innovations. The distinction between radical and
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ncremental innovations is a fundamental one; whereas a radical
nnovation represents a genuinely new product, an incremental
nnovation represents an enhancement or modiﬁcation of an exist-
ng product. The capabilities and resources required to successfully
evelop radical and incremental innovations are different and often
pposed (e.g. Cardinal, 2001; Katz and Tushman, 1981; Laursen
nd Salter, 2006; Lee and Allen, 1982). We  expect that open sci-
nce strategies exert a greater positive effect on a ﬁrm’s ability to
pawn radical innovations than on its ability to spawn incremental
nnovations.
First, open science strategies provide access to external
nowhow that is more valuable in the development of radical
nnovations. The pursuit of radical innovations is associated with
 greater emphasis on the combination of knowledge from inter-
al R&D groups as well as from external communities (Ahuja and
ampert, 2001; Fleming and Sorenson, 2004; Jong, 2011; Katz and
ushman, 1981; Lee and Allen, 1982; Phene et al., 2006). In con-
rast, for the successful pursuit of incremental innovations ﬁrms are
ess dependent on external sources of knowledge. Instead, exper-
ise and knowledge ﬁrms rely on in the development of successful
ncremental innovations is often speciﬁc to a ﬁrm or project (e.g.
iken et al., 1980). Thus, participation in external exchanges of sci-
ntiﬁc knowledge will likely be of more value to the generation of
nnovations that are radically innovative rather than incrementally
nnovative.
Second, the scientiﬁc ‘search mode’ that researchers who engage
n open science employ in research is more beneﬁcial in the devel-
pment of radical than of incremental innovations. Fleming and
orenson (2004) make a distinction between local search and
cience as search modes ﬁrms employ in creative processes under-
ying product innovation. Local search is a search mode that is
losely linked to the concept of exploitation (March and Simon,
958; Cyert and March, 1963/1992; Hansen and Lovas, 2004;
elson and Winter, 1982; Stuart and Podolny, 1996). It implies
hat inventors search incrementally, altering one component of
 product at a time, either reconﬁguring it relative to the other
omponents or replacing it with a different component. Science,
hich is a search mode organized around attempts to generate and
est theories on the other hand offers researchers a ‘map’ in more
omplex search processes, requiring researchers to bring together
reviously uncombined conﬁgurations of coupled, interdependent
echnical components (Fleming and Sorenson, 2004). The theoret-
cal understanding of (the interactions between) the underlying
roperties of technological components that science provides its
ractitioners offers support in the discovery of radical innovations.
uch support for example helps researchers to hypothesize about
roper combinations of components to solve a technical problem or
n identifying useless directions of search before undertaking any
ctual experiments.
Finally, the experimental method of science is thought to bet-
er attune researchers to the negative feedback loops following
ailure that are more commonly associated with the development
f radical innovations (Fleming and Sorenson, 2004). Whereas
he pursuit of incremental innovations can be managed as a
elatively predictable process, the pursuit of radical innovations
s associated with a greater emphasis on experimentation as
ell as higher levels of uncertainty and risk (e.g. March, 1991;
osenkopf and Nerkar, 2001). Researchers who engage in open
cience therefore seem better equipped to succeed in the cre-
tive processes underlying the development of radical innovations.
aken together, these arguments lead to the following hypothe-
is:ypothesis 3. Publishing quality scholarly research has a greater
ositive effect on a ﬁrm’s propensity to produce radical innovations
han on a ﬁrm’s propensity to produce incremental innovations.licy 43 (2014) 645–654
3. Data and methodology
3.1. Research setting and sample
Our research setting is the UK therapeutic biotechnology indus-
try. Commercial R&D in the biotechnology industry is closely
intertwined with university research (Kenney, 1986; McMillan
et al., 2000; Zucker et al., 1998) and the challenges managers face in
organizing biotechnology R&D epitomize the challenges managers
face in managing science-based proprietary R&D (e.g. Cockburn
and Henderson, 1998; Liebeskind et al., 1996; Powell et al., 1996;
Pisano, 2006; Rothaermel and Deeds, 2004). To construct our sam-
ple, we identify all 190 UK-based biotechnology ﬁrms, founded
de novo after 1976 that originated at least one drug development
project between 1999 and 2009 according to the Pharmaprojects
database, which is a leading commercial database that tracks the
development of new therapeutic products and is widely used for
market research in the global pharmaceutical industry.
Further, we  collect bibliographic information from Thomson
Scientiﬁc’s Science Citation Index Expanded and Journal Citation
Report on all publications by researchers afﬁliated with these ﬁrms.
65% of the ﬁrms from our initial sample have at least one publica-
tion in indexed journals over the period 1999–2009 and 93% of
these ﬁrms have at least one article co-authored with an academic
institution. However, the intensity of publishing is not evenly dis-
tributed across ﬁrms; only 16% of ﬁrms published more than 10
papers in total for the whole time span under consideration.
We also use the Pharmaprojects database to collect data on each
ﬁrm’s R&D pipeline and the number of novel therapeutic projects
each ﬁrm moves into (pre)-clinical trials in any given year. The focus
on products in development as a proxy for innovative performance
is appropriate given the importance of development-stage prod-
ucts in this industry as a driver of company value. For example,
in its acquisition of Pharmasset that was announced at the end of
2011, Gilead Sciences in essence paid US$11 Billion for a hepatitis
C drug that was  in clinical trials phase 2 of the drug develop-
ment path (Grocer, 2011). Accordingly, the development of product
pipelines is seen as central in guiding managerial decision making
regarding the deployment of (intellectual) resources and venture
capital investors generally plan exits around product development
milestones that long precede the launch of products.
Next, to gather data on the patent portfolios of ﬁrms, we  rely on
patent applications by these ﬁrms documented by the European
Patent Ofﬁce (EPO). Further, data on R&D investments are obtained
from R&D Scoreboard, which provides information on the UK top
R&D-active companies. Additionally, to collect data on alliances
forged by ﬁrms in our sample, we use the RECAP database, which
offers comprehensive information about alliance formation activi-
ties in the biopharma sector. Moreover, we  use the FAME database
to retrieve corporate information on the ﬁrm total assets, founding
year, group structure, company divisions, subsidiaries, and name
changes.
Our ﬁnal sample is represented by 1033 ﬁrm-year observa-
tions of 160 UK therapeutic biotechnology ﬁrms for the period
1998–2009.
3.2. Measures
3.2.1. Dependent variable
The dependent variable in this study is product innovation
performance and it is measured as the annual count of drugs in
development that enter (pre)clinical trials for the ﬁrst time. Track-
ing the progress of these compounds through further clinical trials
is beyond the scope of this paper.
Our theoretical model predicts that inter-ﬁrm heterogeneity in
capturing the beneﬁts from open science depends on whether an
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nnovation the ﬁrm is developing is radically or incrementally inno-
ative. Following a method used in past research on pharmaceutical
&D (Bierly and Chakrabarti, 1996; Cardinal, 2001; Herrmann and
eine, 2011), we classify projects that represent new chemical enti-
ies (NCEs) as radically innovative. NCEs in our sample are drugs
hat had not previously been approved for human use. Drugs that
re not NCEs are classiﬁed as incrementally innovative. An exam-
le of an incrementally innovative drug would be a drug that was
reviously approved for human use to treat breast cancer, and now
nters clinical trials to gain approval for use in the treatment of
ther types of cancer (e.g. gastric cancer). We  rely for the classiﬁca-
ion of drugs as NCEs or non-NCEs on coding by the Pharmaprojects
ditorial team. We  operationalize the variable radically innova-
ive new products in development as the annual count of new
ompounds that are NCEs; we measure the variable incrementally
nnovative new products in development as the annual count of
ew compounds that are not NCEs.
We  calculate our dependent variables for each year over the
eriod 1999–2009. We  use a one-year lag for the dependent
ariable after the measurement of our independent and control
ariables to allow time to pass between a ﬁrm’s publishing activities
nd the creation of new therapeutic products for clinical devel-
pment. The lead-up time (including the lag) we use to assess
he effect of publications on innovative performance is consis-
ent with estimates of R&D lead-up times for novel ideas to enter
pre)-clinical trials by both management scholars and industry
ractitioners (e.g. Pisano, 2006; The Pharmaceutical Research and
anufacturers of America, 2007). Moreover, the incorporation of
he one-year lag allows us to mitigate potential issues relating to
ndogeneity and reverse causality in our setting (universities might
or example be more interested in collaborating with ﬁrms that
evelop radical innovations, which in turn are more likely to be
ublishable).
.2.2. Independent variables
With the variable impact factor weighted publications we cap-
ure the level of a ﬁrm’s participation and recognition in open
cience communities. Publishing in prominent scholarly journals
s an indicator of the quality of the research performed by ﬁrm
cientists (e.g. Gittelman, 2007). Moreover, publication counts are
idely used not only to proxy a ﬁrm’s scientiﬁc expertise but also
o provide evidence of a ﬁrm’s scientiﬁc contributions to academic
ommunities (e.g. Ding, 2011). We  measure the variable impact fac-
or weighted publications as a publication count weighted by the
mpact factor of the journal for the year 2009. Consistent with past
ork (e.g. McFadyen and Cannella, 2004), this approach measures
he quantity of publications by a ﬁrm’s scientists while accounting
or the quality of these publications. Moreover, it is reasonable to
elieve that the creation of new therapeutic innovations is a func-
ion of a ﬁrm’s stock of knowledge; therefore, to smooth annual
uctuations, we use a three-year window to measure our main
ndependent and control variables.
To check for the robustness of our results, we  create an alter-
ative measure of the ﬁrm’s adoption of open science strategies,
asic research publications, that excludes clinical trials studies.
hile publication counts are widely used as a proxy for the basic
esearch performed by ﬁrms, a trade-off R&D managers face in for-
ulating open science strategies is whether to only share ﬁndings
rom more applied, downstream development activities or to also
isclose a ﬁrm’s more basic, upstream R&D activities. Studies on
pen, user-driven innovation strategies emphasize the importance
f the involvement of users in downstream product development as strategy to encourage the uptake of innovations (e.g. Chesbrough,
003; Von Hippel, 2005). An example of this strategy in the biotech-
ology industry is the publication of results from human subject
tudies that are part of the drug development process, after theselicy 43 (2014) 645–654 649
drugs entered clinical trials. Such publications, ideally co-authored
with clinicians who  are considered thought leaders in their ﬁeld,
are seen as critical in supporting the incorporation and diffusion of
therapeutic innovations in clinical practice. However, clinical tri-
als publications do not generally disclose information about the
underlying biological mechanisms of drugs and therefore do not
necessarily reﬂect a willingness of ﬁrms to disclose proprietary
information and adhere to norms of open science. Also in terms of
their audience clinical trials publications are not as much targeted
at scientists as they are at medical practitioners, whom biotech-
nology ﬁrms wish to encourage to prescribe their products. Finally,
clinical trials studies by deﬁnition deal with products that are
already in the pipeline or on the market and it was prudent to
create an additional measure that excludes these studies from our
sample. To identify basic research publications and exclude clinical
trials publications, we searched in the titles and abstracts of all the
publications in our sample for keywords that denote clinical trials
(i.e. ‘patients’, ‘persons’, ‘subjects’, and ‘clinical trials’). Accordingly
we coded publications as either basic research publications or clin-
ical trials publications. Basic research publications constitute 85.6%
of publications in our sample.
To measure collaborations with universities, we  construct a
dummy  variable that takes the value of 1 if the ﬁrm has at least one
publication co-authored with university scientists within the last
three years; it takes the value of 0, otherwise. We use the authors’
mailing addresses as listed by Science Citation Index Expanded
for each publication to identify universities, colleges, and research
institutes involved in research collaborations with the focal ﬁrm.
In our sample, approximately 72% of all the ﬁrm publications and
73% of the ﬁrm basic research publications are co-authored with
universities.
3.2.3. Control variables
We  include various controls in the estimations. First, to proxy
ﬁrm age we use the difference between the current year and
the company’s founding year. Second, ﬁrm size is measured as
a logarithm of total assets. In addition, the number of products
in development stands for a ﬁrm’s experience in developing new
drugs; this variable is calculated for a three year window. Next,
R&D investment is measured as R&D investment in Million GBP.
Next, we control for a ﬁrm’s prior patenting activity, and count the
number of patent applications at the EPO for a moving window of
three years. The number of patents has been used in the literature
as a proxy for a ﬁrm’s ability to generate new ideas and technologi-
cal knowledge internally (Bierly and Chakrabarti, 1996). Finally, to
account for alternative channels for accessing external knowledge
and competences, we control for whether or not a ﬁrm has entered
into an alliance over the last three years.
3.2.4. Statistical method
We analyze a panel database, comprised of yearly observa-
tions for 160 UK therapeutic biotechnology ﬁrms over the period
1998–2009. Since we employ a panel data format, we control for
time effects. In other words, we  control for factors that vary over
time but affect the entire biotech sector by using a dummy variable
for each year in the examined period. By using ﬁrm ﬁxed effects,
we further control for unobserved heterogeneity at the ﬁrm level, in
other words, for factors such as internal organization, management
style, etc. This estimation procedure results in more conservative
models as the covariates vary within the ﬁrm.
The nature of the dependent variable, namely that of a count
variable taking only non-negative integer values, underlies the
use of negative binomial regression models for hypotheses testing
(Cameron and Trivedi, 1998). An advantage of the negative bino-
mial approach as compared to the Poisson speciﬁcation approach
is that it accounts for overdispersion; in our case this might be a
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Table  1
Description of variables, data and sources.
Variable Description Data source
New products in development (year t + 1) Number of new drugs in development that enter for the
ﬁrst time the ﬁrm’s product development pipeline in
(pre-)clinical trials
Pharmaprojects database
Radically innovative products in development
(year t + 1)
Number of new drugs in development that are new
chemical entities
Pharmaprojects database
Incrementally innovative products in
development (year t + 1)
Number of new drugs in development that are not new
chemical entities
Pharmaprojects database
Collaborations with universities (year t, t − 1,
t  − 2)
A dummy  variable that takes the value of 1 if the ﬁrm has
at least one publication co-authored with university
scientists within the last three years and the value of 0
otherwise
Thomson Scientiﬁc’s Science
Citation Index Expanded
Impact  factor weighted publications (year t,
t − 1, t − 2)
Number of publications weighted by the impact factor of
the journal for the year 2009
Thomson Scientiﬁc’s Science
Citation Index Expanded; 2009
Thomson Reuters Journal Citation
Report – Science Edition
Alliances (year t, t − 1, t − 2) A dummy  variable that takes the value of 1 if the ﬁrm has
entered into an alliance with an external partner over the
last three years and the value of 0 otherwise
RECAP database
Patents (year t, t − 1, t − 2) Number of patent applications at the EPO for a moving
window of three years
European Patent Ofﬁce (EPO)
R&D  investment R&D investment in Million GBP R&D Scoreboard
Firm  size A logarithm of total assets FAME database
Firm  age Difference between the current year and the company’s
founding year
FAME database
Number of products in development (year t, Number of products in development over a window of Pharmaprojects database
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Basic  research publications (year t, t − 1, t − 2) Number of publicatio
clinical trials studies
oncern, given that the variance of the dependent variable exceeds
ts mean. Thus, to account for both overdispersion and ﬁrm-speciﬁc
xed effects, we employ ﬁxed effects negative binomial regressions
o perform the estimations (Hausman et al., 1984).
. Empirical results
Table 1 includes a description of the variables, data and sources.
able 2 reports descriptive statistics, including the means, standard
eviations, minimum and maximum values, and a correlation
atrix among the main variables used in the analysis. On average, a
rm in our sample introduces 0.66 new compounds in development
ach year. The pair-wise correlations among the independent and
ontrol variables are relatively low, suggesting that multicollinear-
ty is unlikely to be problematic in the analysis.
Table 3 presents the results of the ﬁxed effects negative binomial
egression models for new products in development. Our results
re based on an analysis of 1033 ﬁrm-year observations for 160
herapeutic biotechnology ﬁrms. The ﬁndings conﬁrm our main
ypotheses.
Model 1 is the baseline model before including the effect of the
ain independent variables. We  observe a positive and statisti-
ally signiﬁcant effect of alliance activity, number of patents, ﬁrm
ize and ﬁrm age on a ﬁrm’s overall innovative performance. These
esults are not surprising given that in science-based industries
rms rely on both patenting and alliances in new product develop-
ent processes. Hypothesis 1 predicts that impact factor weighted
ublications have a positive impact on the number of new products
n development. In Model 2 we include the number of articles pub-
ished by the ﬁrm over the previous three years, weighted by the
mpact factor of the journal. The beta coefﬁcient of this variable is
ositive and statistically signiﬁcant at level p < 0.05, which provides
mpirical support for Hypothesis 1.
To test Hypothesis 2, we include a dummy  variable, measuring
hether or not the focal ﬁrm has engaged in collaborative research
ith university scientists for the last three years. In support of
ypothesis 2, the beta coefﬁcient of collaborations with university
cientists is positive and signiﬁcant at level p < 0.05, even aftercluding the publications on Thomson Scientiﬁc’s Science
Citation Index Expanded
controlling for the ﬁrm’s publishing activity. The results are
displayed in Models 3 and 4.
Hypothesis 3 predicts that a more substantive publication track
record is more beneﬁcial for radical innovations than it is for incre-
mental innovations. To test this effect, we  follow the methodology
used in past empirical studies (e.g. Bierly et al., 2009; Chatterji and
Fabrizio, 2013; Jansen et al., 2006), and re-estimate the speciﬁca-
tion in Model 4 separately for each type of innovation outcome.
Accordingly, Models 6 and 8 examine the effect of adopting open
science strategies on the type of innovation. The dependent variable
in Model 6 is the count of the radically innovative products in devel-
opment; the beta coefﬁcient of impact factor weighted publications
is positive and statistically signiﬁcant at level p < 0.05, supporting
the prediction that publishing quality research has a positive effect
on ﬁrm radical innovations. The estimated coefﬁcients in Models 4
and 6 suggest that, keeping all other variables constant, an increase
in impact factor weighted publications with one standard deviation
increases the number of new products in development by approx-
imately 16% and the number of radically innovative products in
development by approximately 31%. We  further re-estimate the
same model speciﬁcation (as in Model 4) for incrementally inno-
vative products, and the results are presented in Model 8; the beta
coefﬁcient of impact factor weighted publications is negative and
not statistically signiﬁcant. This ﬁnding shows a different pattern
for ﬁrms’ propensity to develop incremental innovations as com-
pared to radical innovations; engaging in open science fosters the
development of radical innovations (Model 6), but has no effect on
the development of incremental innovations (Model 8). Following
the methodology and reasoning by Bierly et al. (2009), the positive
and signiﬁcant effect of publishing quality research on ﬁrm radi-
cal innovations and its non-signiﬁcant effect on ﬁrm incremental
innovations provide support for Hypothesis 3.
Because of the use of ﬁrm ﬁxed effects and the focus on within
ﬁrm variation over time rather than on across-ﬁrm variation, ﬁrms
that have never introduced any radical innovation are dropped
from the estimation of Model 6, which is the speciﬁcation for
radical innovations. This approach results in more conservative
models (e.g. Benner and Tushman, 2002; Chatterji and Fabrizio,
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2013). Nevertheless, because this analysis is based on a subsample
of ﬁrms that have introduced at least one radical innovation, there
exists a potential concern that those ﬁrms beneﬁt more from
adopting open science regardless of the type of innovations these
ﬁrms develop. To rule out this alternative explanation and a sam-
ple bias, we follow Chatterji and Fabrizio (2013) and re-estimate
Model 8 using the sample of ﬁrms from Model 6. Using the sample
of ﬁrms that have generated at least one radical innovation, we
ﬁnd that the results are comparable to those of Model 8.
To check for robustness of the results, we estimate additional
sets of models. First, we use an alternative measure and consider
only basic research publications for a moving window of three years
(that is, eliminating from the dataset clinical trials publications).
The results are presented in Table 3. Model 5 highlights that the
effect of basic research publications on new products in develop-
ment is positive and statistically signiﬁcant at level p < 0.1, Model
7 highlights that the effect of basic research publications on new,
radically innovative products in development is positive and statis-
tically signiﬁcant at level p < 0.01, and Model 9 highlights that the
effect of basic research publications on new, incrementally inno-
vative products in development is negative and not statistically
signiﬁcant.
Next, we measure publishing by the number of publications by
the ﬁrm over the previous three years, and perform the speciﬁca-
tions in Models 4, 6, and 8. For an alternative test of Hypothesis 2, we
split ﬁrm publications into two subsets: publications co-authored
with university scientists and publications not co-authored with
university scientists, and run the regression speciﬁed in Model 2.
Results across all these speciﬁcations are similar to those reported
in Table 3.
Furthermore, we address a potential concern that some of
the new drugs in development that are not classiﬁed as NCEs in
Pharmaprojects (and are therefore considered incrementally inno-
vative) may  be radically innovative in their application in treating
other diseases. Speciﬁcally, we  coded drugs not classiﬁed as NCEs,
for which a therapeutic use had already been established in a
different therapeutic class than the therapeutic class for which
these compounds were developed, as less incrementally innova-
tive. We  further re-estimated the regression speciﬁed in Model 8
for this subset of drugs not classiﬁed as NCEs, and the results remain
unchanged.
Finally, the issues of potential endogeneity and reverse causal-
ity are always a concern. Beyond using ﬁrm ﬁxed effects and a time
lag in our models, we  control for ﬁrms’ prior innovation output, and
include as a control variable in our regression models, ﬁrm innova-
tive output at time t; the results remain qualitatively unchanged.
5. Discussion and implications
Firms adopting open science strategies are increasingly promi-
nent in the current R&D landscape and this study offers novel
insights into how such strategies support ﬁrms in product inno-
vation. We  highlight that ﬁrms that produce better science enjoy
beneﬁts in new product development. Moreover, we outline
boundary conditions for these beneﬁts. Speciﬁcally, beneﬁts of
open sciences strategies are stronger for the development of radi-
cal product innovations and not signiﬁcant for the development of
incremental innovations. In addition, the beneﬁts of open science
strategies are stronger if these strategies involve collaborations
with academic partners.
This study advances the literature on interdependencies
between ﬁrms’ activities across the realms of open science and
commercial product development in several ways. The current
literature highlights that by publishing, corporate researchers
develop and maintain a ‘proﬁciency in science’ that is key for a
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Table  3
Results of panel data negative binomial regressions with ﬁrm ﬁxed effects for new products in development.
New products in development Radically innovative
products in
development
Incrementally
innovative products in
development
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 Model 9
Basic research
publications (year t,
t − 1, t − 2)
0.039* 0.077*** −0.003
(0.022) (0.029) (0.047)
Impact factor weighted
publications (year t,
t − 1, t − 2)
0.006** 0.005* 0.009** −0.002
(0.003) (0.003) (0.004) (0.007)
Collaborations with
universities (year t,
t − 1, t − 2)
0.411** 0.377** 0.371** 0.433* 0.397 0.188 0.179
(0.176) (0.178) (0.178) (0.250) (0.250) (0.241) (0.246)
Alliances (year t, t − 1,
t  − 2)
0.303* 0.313* 0.276 0.291* 0.288* 0.629*** 0.614** 0.070 0.070
(0.173) (0.173) (0.173) (0.174) (0.174) (0.239) (0.239) (0.235) (0.235)
Patents (year t, t − 1,
t − 2)
0.028*** 0.024*** 0.027*** 0.023*** 0.021** 0.030*** 0.024** 0.038** 0.038**
(0.007) (0.008) (0.007) (0.008) (0.008) (0.009) (0.009) (0.016) (0.017)
R&D  investment 0.017 0.010 0.013 0.007 0.011 0.038 0.053* −0.012 −0.012
(0.017) (0.018) (0.017) (0.018) (0.018) (0.033) (0.031) (0.023) (0.023)
Firm  size 0.109** 0.109** 0.104** 0.104** 0.107** 0.179*** 0.178*** 0.015 0.014
(0.043) (0.043) (0.043) (0.043) (0.043) (0.064) (0.064) (0.054) (0.055)
Firm  age 0.085** 0.081** 0.065 0.065* 0.063 −0.017 −0.034 0.129** 0.130**
(0.040) (0.039) (0.040) (0.039) (0.039) (0.061) (0.061) (0.059) (0.060)
Number of products in
development
−0.096*** −0.112*** −0.098*** −0.112*** −0.113*** −0.185*** −0.197*** −0.079** −0.080**
(0.028) (0.029) (0.028) (0.029) (0.029) (0.039) (0.041) (0.037) (0.037)
Year  dummies Yes Yes Yes Yes Yes Yes Yes Yes Yes
Constant −1.743** −2.356*** −1.672*** −2.337*** −1.661** −3.002*** −2.991*** −1.702** −1.700**
(0.770) (0.584) (0.778) (0.587) (0.779) (0.943) (0.940) (0.740) (0.741)
Number of
observations
1033 1033 1033 1033 1033 646 646 755 755
Number of ﬁrms 160 160 160 160 160 101 101 116 116
Log  likelihood −733.35 −731.34 −730.61 −729.09 −729.10 −369.79 −369.02 −426.56 −426.59
Chi  squared 54.52 58.18 59.48 61.80 62.55 63.19 67.68 29.09 29.07
Standard errors are in parentheses.
ﬁ
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rm’s capability to assimilate and exploit external scientiﬁc knowl-
dge in R&D (Cockburn and Henderson, 1998; Cohen and Levinthal,
990; Deeds et al., 2000; Fabrizio, 2009). We  extend this work
y examining ﬁrms’ innovative performance in light of the qual-
ty and quantity of scholarly contributions by ﬁrm researchers.
peciﬁcally, we add to debates on whether, given the distinctive
tratiﬁcation logics of open science and product development, a
rm’s propensity to conduct better science enhances or hampers
 ﬁrm’s innovative performance (Cockburn and Henderson, 1998;
ittelman and Kogut, 2003). We  ﬁnd conﬁrmation for the for-
er.
Furthermore, we contribute to work on the positive effects of
ollaborations with university scientists for ﬁrm innovation. For
xample, Almeida et al. (2011) highlight a differential effect of
istinctive collaboration types (e.g. scientiﬁc collaborations with
niversities and ﬁrms, and strategic alliances) on ﬁrm innova-
ion, and Fabrizio (2009) underscores the importance of a ﬁrm’s
cientiﬁc orientation in R&D and the degree of connectedness to
niversity scientists for the timing of and the recognition for ﬁrm
nventions. We  extend this work by accounting for the quality of
 ﬁrm’s scientiﬁc publications and the type of a ﬁrm’s innovation
utput.
In addition, our theoretical and empirical examinations of the
ifferential effect of ‘open science’ strategies on distinctive types of
nnovations constitute an important contribution. By considering
istinctive types of innovations, our paper extends past researchthat focuses on the link between the use of scientiﬁc knowledge
and the importance of inventions (e.g. Fabrizio, 2009; Fleming and
Sorenson, 2004). This ﬁnding has important implications for man-
agers and how they set up rules of interaction with open science
communities. Moreover, our use of product development data as a
measure of R&D performance is a methodological innovation in the
literature on R&D that spans the realms of science and technology,
which has traditionally focused on patent data. As we  showcased in
this article, product development data offer great potential for fur-
ther examinations of antecedents of different types of innovation
outcomes.
Our study has several limitations that offer avenues for future
research. First, issues relating to the potential of endogeneity and
reverse causality are always a concern for studies like ours. We
employed commonly used statistical methods to address such con-
cerns. For example, we  used ﬁrm ﬁxed effects and incorporated a
time lag in our models. Furthermore, we  controlled for ﬁrms’ prior
innovation output, and included as a control variable in our regres-
sion models, ﬁrm innovation output at time t. None of the analyses
we conducted to statistically check whether endogeneity was an
issue, qualitatively altered our ﬁndings. However, although the
analyses we  carried out provide us with statistically robust support
for the relationships we identiﬁed, caution about inferring causality
should be observed and further research will be required to develop
richer insights into the mechanisms underlying the examined rela-
tionships.
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Second, there are opportunities to extend our work in the spe-
iﬁc context of the biotechnology industry. Our research question
ertained to the impact of open science strategies on biotechnology
rms’ R&D performance in terms of ﬁrms’ enhanced capabilities to
evelop new products. It did not pertain to possible costs associated
ith the disclosure of R&D ﬁndings that open science strategies
ntail. In particular, we did not consider possible costs relating
o a weaker intellectual property (IP) position and ﬁrms’ reduced
bility to reap the commercial rewards of the enhanced innova-
ive capabilities. Thus, while our paper does highlight beneﬁts
f open science strategies, it does not focus on the costs associ-
ted with these strategies. Building on methodological approaches
sed to analyze paper-patent pairs (e.g. Murray and Stern, 2007),
uture research will be able to clarify the trade-offs managers face
n protecting IP while reaping rewards of open science strate-
ies.
Moreover, this study highlights that the beneﬁts ﬁrms reap
rom adopting open science norms in R&D activities are contingent
n speciﬁc factors such as the type of innovation outcome a ﬁrm
ursues. This insight opens up an avenue for a more comprehen-
ive exploration of other levers managers have at their disposal
n attuning strategic interactions with open science communi-
ies to speciﬁc R&D goals. Innovation antecedents at individual,
rm and network levels of analysis have been highlighted to
e complements or substitutes to one another (e.g. Murray and
’Mahony, 2007; Rothaermel and Hess, 2007). Thus, there is an
pportunity for future research to examine the moderating role
lternative mechanisms for sourcing external knowledge from
pen science communities play in supporting R&D goals such as
orging licensing agreements, recruiting (students of) star scien-
ists in research roles, or participating in pre-competitive research
onsortia.
Third, there are opportunities (and pitfalls) in exploring how
ndings from this study can be generalized beyond the context
f the biotechnology sector. One limitation to the generalizabil-
ty of our research is that there is only a limited number of sectors,
n which academic communities play such an important role in
&D (e.g. Laursen and Salter, 2004). However, there is a growing
umber of sectors, in which like in biotechnology, expert groups
utside the commercial realm play an important role. These for
xample include the computer software sector, where managers
ace dilemmas in deciding whether to share commercially devel-
ped software code in forums of open source communities that are
imilar to the dilemmas managers of biotechnology ﬁrms face in
eciding whether to share R&D work in quality journals (Dahlander,
006; Dahlander and Magnusson, 2005; Henkel, 2006, 2009; Lee
nd Cole, 2003; Von Hippel and von Krogh, 2003). We  believe our
esults hold insights into the considerations that help managers
esolve these dilemmas.
In further examining the applicability of our ﬁndings in other
ndustrial sectors, it will be critical to focus on the distinctive com-
ercialization environments of these other sectors. R&D strategies
hould be contingent on the speciﬁc commercialization environ-
ent of a sector (Gans and Stern, 2003). A critical part of this
nvironment is the IP regime. The commercialization environment
overning innovation in biotechnology is seen as archetypical for
nvironments where IP protection is strong and so-called mar-
ets for ideas prosper as a result (Gans and Stern, 2003). There
re other sectors such as the consumer electronics and soft-
are sectors where IP protection has traditionally been seen as
eaker and the costs of ‘open’ innovation strategies like the ones
iscussed in this paper as higher. Future research will need to
ave a closer look at these differences across sectors and their
mpact on trade-offs R&D managers face in engaging external
xpert groups from outside the commercial realm in product
nnovation.licy 43 (2014) 645–654 653
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